HIV-1 Reverse Transcriptase in Complex with Nevirapine: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== Function of HIV Reverse Transcriptase == | == Function of HIV Reverse Transcriptase == | ||
Reverse Transcriptase is a viral encoded enzyme that converts the viral single-stranded RNA genome into a double-stranded DNA provirus that is integrated into the host chromosome in the host cell's nucleus. The process of converting viral ssRNA into dsDNA that can incorporate into the host chromosome is called retrotranscription, and is characteristic of all retrovirus. HIV-1 reverse transcriptase is encoded by the human immunodeficiency virus, well known as the etiological agent of acquired immunodeficiency syndrome (AIDS). RT consists of two structurally similar subunits, the p66 and p51. The p66 subunit contains two enzymatically active domains, polymerase and RNase H domains. The p55 subunit maintains the proper folding of the p66 domain ensuring its catalytic function. RT carries out several activities related to retrotranscription: RNA and DNA-dependent DNA synthesis, RNase H activity, strand transfer, and strand displacement synthesis. | |||
< | <StructureSection load='3v81' size='350' side='right' caption='Crystal Structure of HIV-1 Reverse Transcriptase with DNA and the nonnucleoside inhibitor nevirapine (PDB entry [[3V81]])' scene=''> | ||
== Nevirapine as an Anti-retroviral Drug == | |||
A wide variety of drugs have been developed to target this enzyme in order to decrease the infectivity of HIV and slow the progression of this chronic disease. One class of drugs, called non-nucleoside reverse transcriptase inhibitors (NNRTIs), contain compounds that bind noncompetitively to a hydrophobic pocket near the polymerase active site. Binding of these compounds inhibit polymerization of nucleic acid by distorting the protein. Nevirapine is a first generation NNRTI, which binds RT in a butterfly-like conformation. Several factors stabilize its interaction with RT's hydrophobic pocket, and the conformational changes it causes in RT essentially inhibits DNA synthesis. Unfortunately, single amino acid mutations in the binding pocket can significantly decrease the antiviral potency of this drug. | |||
</StructureSection> | </StructureSection> | ||
